MedTrace Logo

Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer

NCT04049227 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2025-10-17

No results posted yet for this study

Summary

This early phase I trial studies how well abemaciclib and letrozole work in treating patients with endometrial cancer and determines whether there are changes in patients' cancer cell biomarkers (a genetic feature or specific protein) for cell growth before and after treatment. Antihormone therapy with aromatase inhibitors, such as letrozole, may lessen the amount of estrogen made by the body. Abemaciclib blocks the activities of a class of proteins called cyclin-dependent kinase, which are involved in cell duplication. Giving letrozole and abemaciclib together may slow down cancer cell growth in patients with endometrial cancer.

Conditions

  • Endometrial Endometrioid Adenocarcinoma

Interventions

DRUG

Abemaciclib

Given PO

DRUG

Letrozole

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo standard of care hysterectomy

Sponsors & Collaborators

Principal Investigators

  • Emma Barber, MD, MS · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-12
Primary Completion
2023-04-01
Completion
2023-05-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04049227 on ClinicalTrials.gov